FDA review split for MDCO's cangrelor; shares tumble
This article was originally published in Scrip
Executive Summary
Nervous investors pushed shares of The Medicines Company (MDCO) down about 11% on 10 February after FDA documents revealed a mixed review for the firm's new drug application (NDA) for cangrelor, an intravenous antiplatelet under investigation as a treatment in patients undergoing percutaneous coronary intervention (PCI) and those that require bridging from oral antiplatelet therapy to surgery.